HK1126689A1 - Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders - Google Patents

Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders

Info

Publication number
HK1126689A1
HK1126689A1 HK09105923.2A HK09105923A HK1126689A1 HK 1126689 A1 HK1126689 A1 HK 1126689A1 HK 09105923 A HK09105923 A HK 09105923A HK 1126689 A1 HK1126689 A1 HK 1126689A1
Authority
HK
Hong Kong
Prior art keywords
drug
preparation
treatment
patients suffering
human albumin
Prior art date
Application number
HK09105923.2A
Other languages
English (en)
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of HK1126689A1 publication Critical patent/HK1126689A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
HK09105923.2A 2007-10-26 2009-07-02 Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders HK1126689A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200702831A ES2332846B1 (es) 2007-10-26 2007-10-26 Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.

Publications (1)

Publication Number Publication Date
HK1126689A1 true HK1126689A1 (en) 2009-09-11

Family

ID=40583637

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09105923.2A HK1126689A1 (en) 2007-10-26 2009-07-02 Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders

Country Status (17)

Country Link
US (1) US7851446B2 (es)
EP (1) EP2111868B1 (es)
JP (1) JP5437619B2 (es)
CN (1) CN101417123B (es)
AR (1) AR068901A1 (es)
AU (1) AU2008233025B8 (es)
BR (1) BRPI0804623B8 (es)
CA (1) CA2641830C (es)
CL (1) CL2008003133A1 (es)
ES (2) ES2332846B1 (es)
HK (1) HK1126689A1 (es)
MX (1) MX2008013635A (es)
NZ (1) NZ572131A (es)
PL (1) PL2111868T3 (es)
PT (1) PT2111868E (es)
RU (1) RU2414925C2 (es)
UY (1) UY31418A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood
US10525107B2 (en) 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
EP3484502B1 (en) * 2016-08-18 2021-08-25 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
BR112019022402A2 (pt) * 2017-04-26 2020-05-19 Alkahest Inc regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo
AU2019306477A1 (en) * 2018-07-20 2021-02-11 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
EP3643319A1 (en) * 2018-10-25 2020-04-29 Grifols Worldwide Operations Limited Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages
CN113056275A (zh) 2018-10-26 2021-06-29 万能溶剂有限公司 血浆和血浆组分用于改善疼痛、伤口愈合和术后恢复的用途
CA3215030A1 (en) * 2021-04-30 2022-11-03 Victor Grifols Roura Use of therapeutic plasma exchange and low volume plasma exchange for the treatment of a cognitive impairment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612137A1 (de) 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5112298A (en) 1990-06-25 1992-05-12 Baxter International Inc. Apheresis method and device
US5178603A (en) 1990-07-24 1993-01-12 Baxter International, Inc. Blood extraction and reinfusion flow control system and method
US6627151B1 (en) * 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
JP4851676B2 (ja) 2000-05-23 2012-01-11 ザ ユニバーシティ オブ サザン カリフォルニア アルツハイマー病におけるｌｄｌレセプタータンパク質１（ｌｒｐ−１）の役割
EP1370240A4 (en) * 2001-03-02 2004-09-22 Neuron Therapeutics Inc NEUROPROTECTOR FORMULATIONS AND METHOD
US20050227941A1 (en) 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
US7692011B2 (en) 2002-10-04 2010-04-06 Prana Biotechnology Limited 8-hydroxy and 8-mercapto quinazolinones
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DK1592439T3 (da) 2003-02-13 2007-09-10 Octapharma Ag Fremgangsmåde til fremstilling af en albuminoplösning
JP2007528857A (ja) 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
US7436304B1 (en) 2005-07-19 2008-10-14 Visible Assets, Inc Evidence tracking

Also Published As

Publication number Publication date
CN101417123B (zh) 2012-06-27
JP5437619B2 (ja) 2014-03-12
CA2641830C (en) 2013-07-16
JP2009108059A (ja) 2009-05-21
US20090111740A1 (en) 2009-04-30
CN101417123A (zh) 2009-04-29
ES2332846A1 (es) 2010-02-12
PL2111868T3 (pl) 2014-01-31
ES2332846B1 (es) 2010-07-08
BRPI0804623B8 (pt) 2021-05-25
BRPI0804623B1 (pt) 2020-02-11
NZ572131A (en) 2010-06-25
MX2008013635A (es) 2009-05-11
ES2428698T3 (es) 2013-11-08
AU2008233025B2 (en) 2013-06-27
RU2414925C2 (ru) 2011-03-27
CA2641830A1 (en) 2009-04-26
PT2111868E (pt) 2013-10-17
UY31418A1 (es) 2009-05-29
EP2111868A1 (en) 2009-10-28
CL2008003133A1 (es) 2009-08-07
AU2008233025A1 (en) 2009-05-14
AU2008233025B8 (en) 2013-07-25
RU2008141076A (ru) 2010-04-27
US7851446B2 (en) 2010-12-14
BRPI0804623A2 (pt) 2009-06-30
EP2111868B1 (en) 2013-08-21
AR068901A1 (es) 2009-12-16

Similar Documents

Publication Publication Date Title
HK1126689A1 (en) Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
ZA200808758B (en) Combination therapy for treatment of patients with neurological disorders and cerebral infarction
IL213407A (en) Use of combinations of drug factors to prepare combination therapy drugs
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
IL182105A0 (en) Use of memantine for the preparation of a medicament for the treatment of childhood behavioral disorders
HK1162931A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
HK1258028A1 (zh) 人類抗體及其在神經疾病治療中的診斷和治療用途
IL190652A0 (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
UA81573C2 (en) Use of agomelatine for the preparation of medicaments for the treatment of sleep disorders in depressed patients
TWI369988B (en) New pharmaceutically active compounds for the treatment of respiratory diseases
EP2231148A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE
IL206435A0 (en) Therapeutic regimens for the treatment of immunoinflammatory disorders
ME01951B (me) Upotreba agomelatina za dobijanje lekova namenjenih tretmanu bipolarnih poremećaja
EP2203174A4 (en) THERAPEUTIC REGIMES FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS
IL207977A0 (en) Therapy for disorders of the proximal digestive tract
HRP20040104A2 (en) Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
EP2168575A4 (en) A MEDICAMENT FOR THE TREATMENT OF SUFFERING PATIENTS CAUSED OF INCIDENTIAL ILLNESSES CAUSED BY INCREASED MONOAMINOOXIDASE ACTIVITY AND METHODS OF TREATING PATIENTS SUFFERING FROM DISEASES CAUSED BY INCREASED MONOAMINOOXIDASE ACTIVITY
IL186916A0 (en) Use of insp052 polypeptide for the preparation of a medicament for treating diseases
GB0417474D0 (en) Treatment of respiratory disorders